Table 1 of
Campos-Mollo, Mol Vis 2007;
13:1666-1673.Table 1 of
Campos-Mollo, Mol Vis 2007;
13:1666-1673.
Table 1. Clinical features of patients with either the D380A myocilin mutations (families GJ1-5) or P370L myocilin mutations (family GJ6)
The asterisk indicates the patients diagnosed and treated during the genetic study. The double asterisk denotes IOP records before treatment were not available. The double sharp (hash mark) indicates the number of active principles used as single or combined eye drops at the last examination. In the table, C/D indicates cup-disc ratio of optic nerve, N designates normal, ND indicates not determined, OD is right eye, OS is left eye, U indicates unassessable, SZD denotes superior zone defect, RVFC is remarkable visual field contraction, SHD is superior hemifield depression, SIZD denotes superior and inferior zone defect, and IZD indicates inferior zone defect. The sharp (hash mark) denotes patients who complained of haloes around lights.
Age at
the IOP
time of IOP OD/OI OD/OS Number of
Age at the (mm Hg) (mm Hg) Visual field C/D active Number of
Subject diagnosis study at final alteration ratio principles## surgeries
Family number Diagnosis (years) (years) diagnosis outcome (OD/OS) (OD/OS) (OD/OS) (OD/OS)
------ ------- --------- --------- ------- --------- ------- -------------- ------- ----------- ---------
GJ1 III: 1 JOAG 23 59 26/26 16/16 SZD/N 0.5/0.4 1/1 1/1
III: 2 JOAG 29 57 ** 18/18 RVFC/SHD 0.9/0.8 1/1 1/2
III: 3 JOAG 25 53 22/24 20/16 SZD/RVFC 0.6/0.9 2/2 1/1
IV: 1 JOAG* 38 38 26/24 20/20 N/N 0.5/0.5 1/1 0/0
IV: 2 JOAG 23 31 36/34 12/12 N/N 0.4/0.3 0/0 1/1
IV:3 JOHT* 29 29 24/24 18/19 N/N 0.3/0.3 2/2 0/0
IV: 5 JOAG 17 28 ** 16/16 N/N 0.4/0.3 1/1 0/0
IV: 7 JOAG* 23 32 32/30 14/18 SIZD/SZD 0.8/0.7 0/0 1/1
IV:8 JOAG* 29 29 26/26 12/12 N/N 0.5/0.5 2/2 0/0
V: 3 N ND 2 ND U U 0.2/0.2 0/0 0/0
V: 9 N ND 2 ND U U 0.3/0.3 0/0 0/0
GJ2 II: 2 JOAG 25 60 ** 14/14 RVFC/SZD 1/0.7 2/2 1/1
II: 3 JOAG 20 48 88 15/14 IZD/N 0.5/0.5 0/0 1/1
III: 1 JOHT# 12 31 30/30 13/14 N/N 0.3/0.3 0/0 1/1
III: 3 JOHT 21 21 22/22 18/18 N/N 0.3/0.3 1/1 0/0
GJ3 II: 1 JOAG 29 63 ** 47/12 Amaurosis/RVFC 1/0.9 3/3 5/3
III: 2 JOAG# 10 36 36/36 18/19 SZD/N 0.4/0.2 3/0 4/3
IV: 2 N ND 10 ND 14/14 U 0.2/0.2 0/0 0/0
GJ4 II:3 JOHT 14 36 40/40 13/14 N/N 0.3/0.3 0/0 1/2
GJ5 II:1 JOAG 24 46 ** 30/17 SZD/N 0.5/0.5 3/0 1/1
II: 3 JOAG 27 44 ** 22/18 N/N 0.5/0.6 0/0 1/1
III: 1 N ND 16 ND 18/18 N/N 0.1/0.1 0/0 0/0
III:2 N ND 9 ND 18/18 U 0.1/0.1 0/0 0/0
III:3 N ND 16 ND 21/21 N/N 0.3/0.3 0/0 0/0
III:4 N ND 9 ND 20/20 U 0.1/0.2 0/0 0/0
GJ6 II:2 JOAG 28 30 36/45 18/18 SZD/mild 0.7/0.6 2/1 1/1
diffuse defect
III:1 N ND <1 ND ND ND ND 0/0 0/0
|